RxDoctor Payments Data

Christopher Smith, MD

Urology · Houston, TXNPI 1154401818

Payments from drug & device makers

$53,193in general payments, 2019–2025

Across 62 payments — averaging $857.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$49K
  • Kowa Pharmaceuticals America, Inc.$2K
  • Zimmer Biomet$435
  • Teleflex LLC$401
  • Medtronic$384
  • Neotract Inc.$168
  • plus $620 from 11 others
$6,300in research payments, 2019–2025

Across 2 payments — averaging $3150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$6K

What the payments were for

  • Consulting fees$1,92049%
  • Travel & lodging$2727%
  • Food & beverage$1,73644%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,193 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$217,966
Medicare patients
468
Services billed
19,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron248$227,762
GemtesaVibegron202$180,866
Mirabegron ErMirabegron32$28,033
Estradiol186$12,596
Tamsulosin Hcl620$11,700
Solifenacin Succinate106$6,508
Amikacin Sulfate13$3,386
Oxybutynin Chloride ErOxybutynin Chloride93$3,086
Finasteride171$2,658
Fosfomycin Tromethamine15$2,608
Methenamine Hippurate42$2,557
Alfuzosin Hcl ErAlfuzosin Hcl107$2,115
Silodosin20$1,886
Trospium Chloride38$1,854
Hydroxyzine Hcl97$1,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$76$180,866202 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →